Abstract
Australia is facing a major national medical challenge with the emergence of the Hendra virus (HeV) as a medically and economically important pathogen of humans and animals. Clinical symptoms of human HeV infection can include fever, hypotension, dizziness, encephalitis, respiratory haemorrhage and edema. The window of opportunity for successful patient treatment remains unknown, but is likely to be very narrow. Currently, very few effective therapeutic options are available for the case management of severe HeV infections or the rapid silencing of local outbreaks. This underscores the need for more activity in the drug discovery arena to develop much needed therapeutics that specifically targets this deadly disease. The structural analysis of HeV is very much in its infancy, which leaves many gaps in our understanding of the biology of HeV and makes structure-guided drug design difficult. Structural studies of the viral RNAdependent- RNA polymerase (RdRp), which is the heart of the viral replication machinery, will set the stage for rational drug design and fill a major gap in our understanding of the HeV replication machinery. This review examines the current knowledge based on the multi-domain architecture of the Hendra RdRp and highlights which essential domain functions represent tangible targets for drug development against this deadly disease.
Keywords: Drug, hendra virus, RNA-dependent-RNA polymerase, L protein, P protein, paramyxoviruses.
Current Drug Targets
Title:The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Volume: 15 Issue: 1
Author(s): Tony Velkov, Vincenzo Carbone, Jesmin Akter, Sivashangarie Sivanesan, Jian Li, Travis Beddoe and Glenn A. Marsh
Affiliation:
Keywords: Drug, hendra virus, RNA-dependent-RNA polymerase, L protein, P protein, paramyxoviruses.
Abstract: Australia is facing a major national medical challenge with the emergence of the Hendra virus (HeV) as a medically and economically important pathogen of humans and animals. Clinical symptoms of human HeV infection can include fever, hypotension, dizziness, encephalitis, respiratory haemorrhage and edema. The window of opportunity for successful patient treatment remains unknown, but is likely to be very narrow. Currently, very few effective therapeutic options are available for the case management of severe HeV infections or the rapid silencing of local outbreaks. This underscores the need for more activity in the drug discovery arena to develop much needed therapeutics that specifically targets this deadly disease. The structural analysis of HeV is very much in its infancy, which leaves many gaps in our understanding of the biology of HeV and makes structure-guided drug design difficult. Structural studies of the viral RNAdependent- RNA polymerase (RdRp), which is the heart of the viral replication machinery, will set the stage for rational drug design and fill a major gap in our understanding of the HeV replication machinery. This review examines the current knowledge based on the multi-domain architecture of the Hendra RdRp and highlights which essential domain functions represent tangible targets for drug development against this deadly disease.
Export Options
About this article
Cite this article as:
Velkov Tony, Carbone Vincenzo, Akter Jesmin, Sivanesan Sivashangarie, Li Jian, Beddoe Travis and Marsh A. Glenn, The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114888131204163210
DOI https://dx.doi.org/10.2174/1389450114888131204163210 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology Cytokine Therapy for Cancer
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Multidrug Transporters as Drug Targets
Current Drug Targets Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Current Vascular Pharmacology “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design Cardiovascular Effects Mediated by Imidazoline Drugs: An Update
Cardiovascular & Hematological Disorders-Drug Targets Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Homeostasis and Compensatory Homeostasis: Bridging Western Medicine and Traditional Chinese Medicine
Current Cardiology Reviews Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets